Farnesyl Transferase

Ftase

Farnesyltransferase is one of the three enzymes in the prenyltransferase group. Farnesyltransferase's targets include members of the Ras superfamily of small GTP-binding proteins critical to cell cycle progression.

Farnesyltransferase inhibitors (FTIs) are small-molecule inhibitors that selectively inhibit farnesylation of a number of intracellular substrate proteins such as Ras. Farnesyl transferase inhibitors (FTIs) represent a new class of signaling inhibitors that is emerging in the clinical arena of hematologic malignancies and that may inhibit critical growth and survival signals. FTIs are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras (protein), which is commonly abnormally active in cancer.

Farnesyl Transferase Inhibitors

ABT-100

Cat. No.: HY-119257

ABT-100 is a potent, highly selective and orally active **farnesyltransferase** inhibitor.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg

Arglabin

((+)-Arglabin)

Cat. No.: HY-16059

Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a **NLRP3 inflammasome** inhibitor. Arglabin shows anti-inflammatory and antitumor activities.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-214662

Cat. No.: HY-16111

BMS-214662 is a potent and selective **farnesyl transferase** inhibitor with potent antitumor activity with an IC_{50} of 1.35 nM.



Purity: 99.59%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGTI-2734

Cat. No.: HY-128350

FGTI-2734 is a RAS C-terminal mimetic dual **farnesyl transferase (FT)** and **geranylgeranyl transferase-1 (GGT-1)** inhibitor with IC_{50}s of 250 nM and 520 nM for FT and GGT-1, respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FGTI-2734 mesylate

Cat. No.: HY-128350A

FGTI-2734 mesylate is a RAS C-terminal mimetic dual **farnesyl transferase (FT)** and **geranylgeranyl transferase-1 (GGT)** inhibitor with IC_{50}s of 250 nM and 520 nM for FT and GGT, respectively.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FTI 276

Cat. No.: HY-15873

FTI-276 is a **protein farnesyl transferase (PFT)** inhibitor with IC_{50}s of 0.9 and 0.5 nM for Plasmodium falciparum and human.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

FTI 276 TFA

Cat. No.: HY-15873A

FTI-276 is a **protein farnesyl transferase (PFT)** inhibitor with IC_{50}s of 0.9 nM and 0.5 nM for Plasmodium falciparum and human, respectively.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FTI-2148

Cat. No.: HY-118916

FTI-2148 is a RAS C-terminal mimetic dual **farnesyl transferase (FT-1)** and **geranylgeranyl transferase-1 (GGT-1)** inhibitor with IC_{50}s of 1.4 nM and 1.7 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTI-2153

Cat. No.: HY-123242

FTI-2153 is a potent and highly selective inhibitor of **farnesyltransferase (FTase)**, with an IC_{50} of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC_{50}, 10 nM) than Rap1A processing. Anti-cancer activity.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FTI-277

Cat. No.: HY-15872

FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTI-277 hydrochloride

Cat. No.: HY-15872A

FTI-277 hydrochloride is an inhibitor of **farnesyl transferase (FTase)**; a highly potent Ras CAAX peptidomimetic which antagonizes both **H-** and **K-Ras oncogenic signaling**. FTI-277 hydrochloride can inhibits **hepatitis delta virus (HDV)** infection.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-778123 hydrochloride

(L-778,123 hydrochloride)

Cat. No.: HY-16273A

L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lapaquistat acetate

(TAK-475)

Cat. No.: HY-16274

Lapaquistat acetate (TAK-475) is a **squalene synthase** inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lonafarnib

(Sch66336)

Cat. No.: HY-15136

Lonafarnib is an orally bioavailable farnesyl protein transferase (**FPTase**) inhibitor for H-ras, K-ras and N-ras with $\mathbf{IC_{50}}$ of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib has anti-**hepatitis delta virus (HDV)** activities.



Purity: 98.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Manumycin A

Cat. No.: HY-N6796

Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein **farnesyltransferase (FTase)** with respect to farnesylpyrophosphate ($\mathbf{K_i}$ =1.2 μM), and as a noncompetitive inhibitor with respect to the **Ras** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

RPR107393 free base

Cat. No.: HY-100299

RPR107393 free base is a selective **squalene synthase** inhibitor, which inhibits rat liver microsomal squalene synthase with an $\mathbf{IC_{50}}$ of 0.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tectol

Cat. No.: HY-N7634

Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM. Tectol is a **farnesyltransferase (FTase)** inhibitor with $\mathbf{IC_{50}}$s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tipifarnib

(IND 58359; R115777)

Cat. No.: HY-10502

Tipifarnib (IND 58359) binds to and inhibits **farnesyltransferase (FTase)** with an $\mathbf{IC_{50}}$ of 0.86 nM. Antineoplastic activity.



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tipifarnib (S enantiomer)

(IND-58359 S enantiomer; (S)-(-)-R-115777)

Cat. No.: HY-10502A

Tipifarnib S enantiomer is the S-enantiomer of Tipifarnib. Tipifarnib is a potent and specific **farnesyltransferase (FTase)** inhibitor with $\mathbf{IC_{50}}$ of 0.6 nM. Tipifarnib S enantiomer is the less active isomer.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

YM-53601 free base

Cat. No.: HY-100313

YM-53601 free base is a **squalene synthetase** inhibitor which suppresses lipogenic biosynthesis and lipid secretion in rodents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg